Eli Lilly signed an agreement with Cipla, allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a ...

Eli Lilly ( NYSE: LLY) has partnered with India's Cipla to market its weight-loss medication Tirzepatide under a new brand in ...

While Eli Lilly LLY is a market leader in the GLP-1 segment, thanks to its tirzepatide medicines Mounjaro and Zepbound (for ...

In a move aimed at expanding access to obesity and diabetes care in India, Eli Lilly and Company (India) Pvt. Ltd. (Lilly) ...

On Oct. 30, Eli Lilly will announce third-quarter earnings results that could lift the stock, or pressure it further. Here ...

Analysts say that while the deal is a positive for the stock, it has already been priced in and investors are now resorting ...

Lilly’s legal offensive against compounders of its popular weight loss drugs hits another snag in court.

Indian pharma giant Cipla on Thursday announced an agreement with US pharmaceutical firm Eli Lilly, acquiring the rights to ...

Per the agreement, the Indianapolis-based drugmaker will continue to manufacture the drug, which India-based Cipla will sell under a new brand name.

Cipla and Eli Lilly India have announced an agreement to distribute a type 2 diabetes drug, tirzepatide, under the new brand ...

Under the agreement, Cipla will market the drug under a new brand name, Yurpeak, while Lilly continues to sell it as Mounjaro ...